Loading clinical trials...
Loading clinical trials...
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Conditions
Interventions
AGS-16C3F
Axitinib
Locations
26
United States
Site US01026
Tucson, Arizona, United States
Site US01008
La Jolla, California, United States
Site US01007
Los Angeles, California, United States
Site US01020
Los Angeles, California, United States
Site US01019
Palo Alto, California, United States
Site US01010
Atlanta, Georgia, United States
Start Date
May 3, 2016
Primary Completion Date
October 2, 2020
Completion Date
October 2, 2020
Last Updated
November 18, 2024
NCT04693377
NCT06500455
NCT06863311
NCT07123090
NCT06391099
NCT07227415
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions